Association Between 18F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma

详细信息    查看全文

• 作者：Suk Hyun Lee ; Sangwon Han ; Hyo Sang Lee…
• 关键词：18F ; fluorodeoxyglucose ; Positron ; emission tomography ; BRAF mutation ; Papillary thyroid carcinoma
• 刊名：Nuclear Medicine and Molecular Imaging
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：50
• 期：1
• 页码：38-45
• 全文大小：417 KB
• 参考文献：1.Kaida H, Hiromatsu Y, Kurata S, Kawahara A, Hattori S, Taira T, et al. Relationship between clinicopathological factors and fluorine-18-fluorodeoxyglucose uptake in patients with papillary thyroid cancer. Nucl Med Commun. 2011;32(8):690–8.CrossRef PubMed
  2.Kim BS, Kim SJ, Kim IJ, Pak K, Kim K. Factors associated with positive F-18 flurodeoxyglucose positron emission tomography before thyroidectomy in patients with papillary thyroid carcinoma. Thyroid. 2012;22(7):725–9.PubMedCentral CrossRef PubMed
  3.Kim MH, Ko SH, Bae JS, Lee SH, Jung CK, Lim DJ, et al. Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma. Thyroid. 2013;23(11):1452–60.CrossRef PubMed
  4.Duntas L, Grab-Duntas BM. Risk and prognostic factors for differentiated thyroid cancer. Hell J Nucl Med. 2006;9(3):156–62.PubMed
  5.Yun M, Noh TW, Cho A, Choi YJ, Hong SW, Park CS, et al. Visually discernible [18F]fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor. J Clin Endocrinol Metab. 2010;95(7):3182–8.CrossRef PubMed
  6.Jeong HS, Chung M, Baek CH, Ko YH, Choi JY, Son YI. Can [18F]-fluorodeoxyglucose standardized uptake values of PET imaging predict pathologic extrathyroid invasion of thyroid papillary microcarcinomas? Laryngoscope. 2006;116(12):2133–7.CrossRef PubMed
  7.Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12(2):245–62.CrossRef PubMed
  8.Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab. 2010;95(9):4197–205.CrossRef PubMed
  9.Riesco-Eizaguirre G, Santisteban P. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr Relat Cancer. 2007;14(4):957–77.CrossRef PubMed
  10.Xi X, Han J, Zhang JZ. Stimulation of glucose transport by AMP-activated protein kinase via activation of p38 mitogen-activated protein kinase. J Biol Chem. 2001;276(44):41029–34.CrossRef PubMed
  11.Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996;37(9):1468–72.PubMed
  12.Kim S, Chung JK, Min HS, Kang JH, do Park J, Jeong JM, et al. Expression patterns of glucose transporter-1 gene and thyroid specific genes in human papillary thyroid carcinoma. Nucl Med Mol Imaging. 2014;48(2):91–7.PubMedCentral CrossRef PubMed
  13.Mian C, Barollo S, Pennelli G, Pavan N, Rugge M, Pelizzo MR, et al. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf). 2008;68(1):108–16.CrossRef
  14.Barollo S, Pennelli G, Vianello F, Watutantrige Fernando S, Negro I, Merante Boschin I, et al. BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability. Eur J Endocrinol. 2010;163(4):659–63.CrossRef PubMed
  15.Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, et al. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40(7):985–96.PubMedCentral CrossRef PubMed
  16.Geworski L, Knoop BO, de Cabrejas ML, Knapp WH, Munz DL. Recovery correction for quantitation in emission tomography: a feasibility study. Eur J Nucl Med. 2000;27(2):161–9.CrossRef PubMed
  17.Nagarajah J, Ho AL, Tuttle RM, Weber WA, Grewal RK. Correlation of BRAFV600E mutation and glucose metabolism in thyroid cancer patients: an 18F-FDG PET study. J Nucl Med. 2015;56(5):662–7.CrossRef PubMed
  18.Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21(3):297–308.PubMedCentral CrossRef PubMed
  19.Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20(2):379–87.CrossRef PubMed
  20.van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer. 2007;43(9):1392–8.CrossRef PubMed
  21.Westerterp M, Sloof GW, Hoekstra OS, Ten Kate FJ, Meijer GA, Reitsma JB, et al. 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol. 2008;134(2):227–36.CrossRef PubMed
  22.Yen TC, See LC, Lai CH, Yah-Huei CW, Ng KK, Ma SY, et al. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med. 2004;45(1):22–9.PubMed
  23.Kim BH, Kim IJ, Kim SS, Kim SJ, Lee CH, Kim YK. Relationship between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in incidentally detected thyroid cancer. Cancer Biother Radiopharm. 2010;25(3):309–15.CrossRef PubMed
  24.Zerilli M, Zito G, Martorana A, Pitrone M, Cabibi D, Cappello F, et al. BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer. Mod Pathol. 2010;23(8):1052–60.CrossRef PubMed
  25.Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.CrossRef PubMed
  26.Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26(29):4714–9.PubMedCentral CrossRef PubMed
  27.Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27(10):1675–84.PubMedCentral CrossRef PubMed
  28.Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol. 2012;167(5):643–50.CrossRef PubMed
  29.Marotta V, Ramundo V, Camera L, Del Prete M, Fonti R, Esposito R, et al. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin Endocrinol (Oxf). 2013;78(5):760–7.CrossRef
  30.Hachemi M, Couturier O, Vervueren L, Fosse P, Lacoeuille F, Urban T, et al. (8)F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients. PLoS One. 2014;9(2):e87629.PubMedCentral CrossRef PubMed
  31.Sunaga N, Oriuchi N, Kaira K, Yanagitani N, Tomizawa Y, Hisada T, et al. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer. 2008;59(2):203–10.CrossRef PubMed
  32.Takahashi R, Hirata H, Tachibana I, Shimosegawa E, Inoue A, Nagatomo I, et al. Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res. 2012;18(1):220–8.CrossRef PubMed
  33.Tiseo M, Ippolito M, Scarlattei M, Spadaro P, Cosentino S, Latteri F, et al. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib. Cancer Chemother Pharmacol. 2014;73(2):299–307.CrossRef PubMed
  34.Boellaard R. Need for standardization of 18F-FDG PET/CT for treatment response assessments. J Nucl Med. 2011;52 Suppl 2:93s–100s.CrossRef PubMed
  
• 作者单位：Suk Hyun Lee (1)
  Sangwon Han (1)
  Hyo Sang Lee (1)
  Sun Young Chae (1)
  Jong Jin Lee (1)
  Dong Eun Song (2)
  Jin-Sook Ryu (1)
  
  1. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea
  2. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
  
• 刊物主题：Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1869-3482

文摘

Purpose The BRAF mutation, a potential prognostic factor in papillary thyroid carcinoma (PTC), is associated with a high expression of the glucose transporter gene. We investigated which clinicopathologic factors, including BRAF mutation status, influence 18F-fluoro-2-deoxyglucose (18F-FDG) avidity.